Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ARVN Arvinas > Company Profile
ARVN Arvinas
41.390
+1.640+4.13%
Post Mkt Price
41.3900.0000.00%
Symbol
ARVN
Company Name
Arvinas
Listing Date
09/27/2018
Establishment Date
2013
CEO
Dr. John G. Houston, PhD
Market
NASDAQ
Employees
280
Securities Type
DR
Fiscal Year Ends
12-31
Address
5 Science Park,395 Winchester Avenue
City
New Haven
Province
Connecticut
Country
United States of America
Zip code
06511
Phone
1-203-535-1456
Profile
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Company Overview
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Listing Date: 09/27/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist